Glutarate — predicted protein targets

Known targets — ChEMBL curated mechanism

ADRA1A ADRA1B ADRA1D ADRA2A ADRA2B ADRA2C ADRB1 ADRB2 ADRB3 CALCRL CHRM1 CHRM2 CHRM3 F2R MAOA MAOB MAP2K1 MAP2K2 NTRK1 NTRK2 NTRK3 OPRD1 OPRK1 OPRM1 P2RY12 PKLR SCN10A SCN11A SCN1A SCN2A SCN3A SCN4A SCN5A SCN7A SCN8A SCN9A SLC18A2 SLC6A2 SLC6A3 TLR7 TLR9 TUBA1A TUBA1B TUBA1C TUBA3C TUBA3E TUBA4A TUBB TUBB1 TUBB2A TUBB2B TUBB3 TUBB4A TUBB4B TUBB6 TUBB8 dacA dacB dacC folA ftsI mrcA mrcB mrdA pol rplA rplB rplC rplD rplE rplF rplI rplJ rplK rplL rplM rplN rplO rplP rplQ rplR rplS rplT rplU rplV rplW rplX rplY rpmA rpmB rpmB1 rpmB2 rpmC rpmD rpmE rpmE2 rpmF rpmG rpmG1 rpmG2 rpmH rpmI rpmJ rpmJ2 rpsA rpsB rpsC rpsD rpsE rpsF rpsG rpsH rpsI rpsJ rpsK rpsL rpsM rpsN rpsO rpsP rpsQ rpsR rpsR1 rpsR2 rpsS rpsT rpsU rpsZ ykgM ykgO

The experimentally established mechanism targets of Glutarate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	SLC22A6	Q4U2R8	2/20	0.73

▸	LMNA	P02545	4/20	0.62

▸	TSHR	P16473	4/20	0.59

▸	NFKB1	P19838	2/20	0.59

▸	PMP22	Q01453	1/20	0.59

▸	CAMK2A	Q9UQM7	1/20	0.53

▸	APEX1	P27695	1/20	0.50

▸	GABRR3	A8MPY1	1/20	0.50

▸	GABRP	O00591	1/20	0.50

▸	GABRD	O14764	1/20	0.50

▸	HDAC3	O15379	1/20	0.50

▸	GABBR2	O75899	1/20	0.50

▸	CYP1A2	P05177	1/20	0.50

▸	THRB	P10828	1/20	0.50

▸	GABRA1	P14867	1/20	0.50

▸	GABRB1	P18505	1/20	0.50

▸	GABRG2	P18507	1/20	0.50

▸	GABRR1	P24046	1/20	0.50

▸	GABRB3	P28472	1/20	0.50

▸	GABRR2	P28476	1/20	0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
Adipic Acid SCHEMBL540745	0.93	LMNA (0.73)	SLC22A6LMNATSHRNFKB1PMP22
Adipic Acid SCHEMBL28221050	0.90	LMNA (0.69)	SLC22A6LMNATSHRNFKB1PMP22
Sulfuric Acid SCHEMBL27476208	0.90	TSHR (0.75)	SLC22A6LMNATSHRNFKB1PMP22
Azelaic Acid SCHEMBL29124511	0.88	TSHR (0.71)	SLC22A6LMNATSHRNFKB1PMP22
Glutarate SCHEMBL9281949	0.88	SLC22A6 (0.65)	SLC22A6LMNATSHRNFKB1PMP22
Azelaic Acid SCHEMBL29124519	0.88	TSHR (0.71)	SLC22A6LMNATSHRNFKB1PMP22
Succinic Acid SCHEMBL285597	0.86	LMNA (0.69)	SLC22A6LMNATSHRNFKB1PMP22
Glutarate SCHEMBL6701735	0.86	—	—
Glutarate SCHEMBL7414	0.86	—	—
Glutarate SCHEMBL27601182	0.86	SLC22A6 (1.00)	SLC22A6LMNATSHRNFKB1PMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-11896697-B2	Composition for keratin fibers	L'OREAL (FR)	2024-02-13	—	—	US	disclosed
EP-4308093-A1	TOPICAL PHARMACEUTICAL COMPOSITION COMPRISING AMITRIPTYLINE AND AN ALKALINE AQUEOUS PHASE	Algotherapeutix (FR)	2024-01-24	—	—	EP	disclosed
US-20230103300-A1	TOPICAL PHARMACEUTICAL COMPOSITION IN GEL FORM COMPRISING AT LEAST AMITRIPTYLINE FOR USE IN THE TREATMENT OF CORONAVIRUS-INDUCED NEUROPATHIC PAIN	ALGOTHERAPEUTIX (FR)	2023-04-06	—	—	US	disclosed
US-20230103462-A1	TOPICAL PHARMACEUTICAL COMPOSITION IN GEL FORM COMPRISING AT LEAST AMITRIPTYLINE FOR USE IN THE TREATMENT OF NEUROPATHIC PHANTOM LIMB PAIN	ALGOTHERAPEUTIX (FR)	2023-04-06	—	—	US	disclosed
EP-4159195-A1	TOPICAL PHARMACEUTICAL COMPOSITION IN GEL FORM COMPRISING AT LEAST AMITRIPTYLINE FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN INDUCED BY A CORONAVIRUS	Algotherapeutix (FR)	2023-04-05	—	—	EP	disclosed
EP-4159196-A1	TOPICAL PHARMACEUTICAL COMPOSITION IN GEL FORM COMPRISING AT LEAST L AMITRIPTYLINE FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN FROM THE PHANTOM LIMB	Algotherapeutix (FR)	2023-04-05	—	—	EP	disclosed
EP-4106726-A1	TOPICAL PHARMACEUTICAL COMPOSITION IN THE FORM OF AN AQUEOUS GEL COMPRISING AT LEAST AMITRIPTYLINE	Algotherapeutix (FR)	2022-12-28	—	—	EP	disclosed
US-20220387594-A1	USE OF AMITRIPTYLINE AND/OR ONE OF THE PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS A PRESERVATIVE	ALGOTHERAPEUTIX (FR)	2022-12-08	—	—	US	disclosed
EP-4098249-A1	USE OF AMITRIPTYLINE AND/OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS AS A PRESERVATIVE AGENT	Algotherapeutix (FR)	2022-12-07	—	—	EP	disclosed
WO-2022117809-A1	PAPER PULP AND USES THEREOF	GUIBOUT PIERRE ANTOINE (FR)	2022-06-09	—	—	WO	disclosed
WO-2010070233-A2	KIT FOR COATING KERATIN SUBSTANCES COMPRISING A POLYSACCHARIDE AND A CHEMICAL CROSSLINKING AGENT	L'OREAL (FR)	2010-06-24	—	—	WO	disclosed
WO-2010070234-A2	KIT FOR COATING KERATIN SUBSTANCES COMPRISING A POLYSACCHARIDE AND AN IONIC OR DATIVE COMPLEXING AGENT	L'OREAL (FR)	2010-06-24	—	—	WO	disclosed
EP-2198846-A1	Oxidative hair dye composition comprising a fatty component, a thickener and a dye precursor.	L'OREAL (FR)	2010-06-23	—	—	EP	disclosed
WO-2010029267-A1	COSMETIC COMPOSITION CONTAINING QUATERNARY AMMONIUM ESTERS AND THICKENING POLYMERS, AND USE FOR HAIR CONDITIONING	L'OREAL (FR)	2010-03-18	—	—	WO	disclosed
EP-1992329-A1	Dyeing composition comprising an aminopyrazolopyridine oxidation base and a specific associative polymer	L'Oréal (FR)	2008-11-19	—	—	EP	disclosed
EP-1404288-B1	COMPOSITION FOR OXIDATION DYEING OF KERATINOUS FIBRES COMPRISING A AMINO PYRAZOLE AND A CELLULOSE COMPOUND	OREAL (FR)	2008-10-29	—	—	EP	disclosed
EP-1340485-B1	Aerosol foam composition containing a combination of a cationic vinylpyrrolidone polymer and a nonionic cellulosic compound and its use in cosmetics	OREAL (FR)	2008-02-13	—	—	EP	disclosed
EP-1404288-A2	COMPOSITION FOR OXIDATION DYEING OF KERATINOUS FIBRES COMPRISING A AMINO PYRAZOLE AND A CELLULOSE COMPOUND	L'OREAL (FR)	2004-04-07	—	—	EP	disclosed
EP-1340485-A2	Aerosol foam composition containg a combination of a vinylpyrrolidone cationic polymer and a cellulosic compound and its use in cosmetics	L'OREAL (FR)	2003-09-03	—	—	EP	disclosed
WO-2002051372-A2	COMPOSITION FOR OXIDATION DYEING OF KERATINOUS FIBRES COMPRISING A AMINO PYRAZOLE AND A CELLULOSE COMPOUND	L'OREAL (FR)	2002-07-04	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-11896697-B2	Composition for keratin fibers	KRT18, PRKCZ, PRKCH	SLC22A6 4368/4885LMNA 2738/4885TSHR 4415/4885
US-20230103462-A1	TOPICAL PHARMACEUTICAL COMPOSITION IN GEL FORM COMPRISING AT LEAST AMITRIPTYLINE FOR USE IN THE TREATMENT OF NEUROPATHIC PHANTOM LIMB PAIN	PMP22, GAP43, SUCLG1	SLC22A6 1909/4885LMNA 2601/4885TSHR 4792/4885
US-20220387594-A1	USE OF AMITRIPTYLINE AND/OR ONE OF THE PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS A PRESERVATIVE	TPH2, TPH1, SLC6A2	SLC22A6 333/4885LMNA 217/4885TSHR 3356/4885
US-20230103300-A1	TOPICAL PHARMACEUTICAL COMPOSITION IN GEL FORM COMPRISING AT LEAST AMITRIPTYLINE FOR USE IN THE TREATMENT OF CORONAVIRUS-INDUCED NEUROPATHIC PAIN	GAP43, ACHE, ACE2	SLC22A6 1950/4885LMNA 2519/4885TSHR 4861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.